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Patients with COPD are at risk for other comorbid diseases, like heart failure, coronary heart
disease, and depression. However, little is known about COPD phenotypes and prevalence of
sub-clinical renal failure.
433 COPD patients and 233 subjects without COPD, from Western Norway, age 40e75, GOLD
stage IIeIV, were examined in 2006/07 upon entry to the Bergen COPDCohort Study. Plasma creat-
inine wasmeasured in 422 of the COPD patients. The Glomerular Flow Rate (GFR) was determined
with the Cockcroft Gault formula, and having a GFR < 60 was defined as renal failure. Examined
explanatory factors were sex, age, smoking habits, GOLD stage, hypoxemia, exacerbation history,
cachexia, use of daily inhaled steroids, Charlson comorbidity score, use of ACE inhibitors and/or
ARBs, and the inflammatory plasma markers C-reactive protein (CRP), soluble tumor necrosis
factor receptor 1 (sTNF-R1) and neutrophil gelatinase associated lipocalin (NGAL). Associations
between explanatory variables and renal failure were examined by a logistic regression analysis.
The prevalence of having GFR < 60 was 9.6% in female COPD patients and 5.1% in male COPD
patients (pZ 0.08). Inmultivariable analysis, female sex, higher age, cachexia, and the inflamma-
tory markers sTNF-R1 and NGAL were all independently associated with a higher risk for renal
failure,whereas use of inhaled steroids, Charlson score,GOLD stage, respiratory failure, andexac-
erbation frequency were not.
Undiagnosed renal failure is a concern particularly in elderly COPD patients and COPD patients
with cachexia.
ª 2011 Elsevier Ltd. All rights reserved.racic Medicine, Haukeland University Hospital, Jonas Liesvei 65, 5021 Bergen, Norway. Tel.: þ47 95
.uib.no (T.M.L. Eagan).
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362 B. Gjerde et al.Chronic Obstructive Pulmonary Disease (COPD) is a multi-
factorial inflammatory disease. COPD affects the airways
and lung parenchyma where it causes progressive and
irreversible airflow limitation. COPD is caused mainly by
inhalation of toxic particles and gases like in tobacco
smoke,1 but inherited factors may also contribute to the
development.2
COPD affects 9e10% of adults over the age of 40 years,3
and the prevalence increases with age. In 2004, COPD was
the fifth leading cause of death, and the mortality rate is
rising.4 Patients with COPD have a high frequency of
comorbidities.5 The most frequent comorbid diseases are
hypertension and heart failure, depression and anxiety,
diabetes, osteoporosis, lung cancer and cachexia.6 The
inflammatory component and frequent comorbidities has
led to a common view that COPD is a systemic inflammatory
disease affecting many organs or biological mechanisms.
Especially heart- and coronary diseases, depression
and cachexia are known to have an inflammatory
component.7e9
Renal failure is usually defined using one of several
different formulas, most of which includes measured blood
creatinine.10 As most patients developing renal failure will
have an asymptomatic rise in creatinine over time, many
COPD patients may have an undiagnosed renal failure well
before being discovered. Renal failure is a significant risk
factor for cardiovascular diseases; conditions which COPD
patients are at risk for, particularly with increasing severity
of COPD.11 Polypharmacy is frequent in COPD patients, and
undiagnosed renal failure could increase the risk of adverse
reactions. Finally, both COPD and renal failure are associ-
ated with an increase in systemic inflammation,12e14 which
potentially could add to the complications of either
disease.
However, the relationship between renal failure and
COPD is largely undescribed. To date, only one Italian study
has examined the prevalence of renal failure in COPD
patients.15 The Italian study of 356 elderly COPD patients,
found a high prevalence of renal failure, 43%, of which half
had known renal failure and half undiagnosed renal failure.
Such a high prevalence of undiagnosed renal failure
as this is likely to have important consequences for
our treatment of COPD, but needs to be confirmed in other
studies. In particular, the relationship between COPD
severity and undiagnosed renal failure needs to be
assessed.
The purpose of the current study was to estimate the
frequency of undiagnosed renal failure in a population of
COPD patients, and to examine if there was an association
between important COPD characteristics, including
inflammatory markers, and renal failure.
Materials and methods
Study population
The baseline survey of the Bergen COPD Cohort Study (BCCS)
was conducted between February 2006 and September
2007, and a total of 433 COPD patients and 233 subjects
without COPD, aged 40e76 years, were examined.12 Most of
the patients were recruited from health institutions inHordaland County in Western Norway, whereas the subjects
without COPD were recruited among former participants
from a general population survey from Hordaland County.16
The sampling and data collection in the BCCS have previ-
ously been published in detail.12
Briefly, a study physician examined all subjects, and
reported a full medical history based on patient interview
and hospital journals. Exacerbations history, comorbidities,
smoking habits and use of medications were recorded.
Causes for exclusion were known renal failure requiring
treatment, rheumatoid arthritis, systemic lupus eryth-
ematosus or other connective tissue disorders, inflamma-
tory bowel disease or active cancer during the last five
years. Participants with other diseases like heart failure,
coronary heart disease, hypertension or diabetes were not
excluded.
All COPD patients were required to meet the following
spirometry criteria: Having a post-bronchodilator FEV1/FVC
ratio < 0.7, and an FEV1 < 80% predicted based on
Norwegian pre-bronchodilation reference values.17
Furthermore, COPD patients had to have a smoking
history of 10 pack-years to be included. Patients were not
admitted into the study while having an active exacerba-
tion defined as having received oral steroids or antibiotics
the last 4 weeks.
All participants received written information, and
a consent signature was required before acceptance into
the study. All participation was voluntary. The regional
ethical committee approved the study.Data sampling
Spirometry was performed using a Viasys Masterscope,
before and 15 min after inhalation of 0.4 mg salbutamol.
Weight and height were recorded for every subject. The fat
free mass index (FFMI, kg/m2) was estimated with
bioelectrical impedance measurements, using a Bodystat
1500 (Bodystat Ltd, Isle of Man, UK) after an overnight
fasting period. Cachexia was defined as having an FFMI
below 17 kg/m2 for men and below 14 kg/m2 for women.18
Arterial oxygen tension (Pa02) was estimated with a Radi-
ometer ABL 520 blood gas analyzer.
The plasma samples were centrifugated within 30 min at
2150 g for 15 min at 4 C. The samples were stored at
80 C and thawed < 3 times. The inflammatory markers C-
reactive protein (CRP), soluble tumor necrosis factor
receptor 1 (sTNF-R1), and neutrophil gelatinase associated
lipocalin (NGAL) were analyzed by enzyme immunoassays
(EIAs), as described in a former study.12 Plasma creatinine
levels were measured by routine laboratory methods
(Modular PP, Roche Diagnostics, Basel, Switzerland).Definition of renal failure
The Glomerular Filtration Rate (GFR) was determined with
the Cockcroft Gault formula, which takes into account sex,
age, weight and creatinine.19 A GFR < 60 was defined as
renal failure, according to the Kidney Disease Outcomes
Quality Initiative (K/DOQI) guidelines classifications.20
Table 1 The baseline characteristics of 433 patients in
the Bergen COPD cohort study.a
Women,
n Z 175
Men,
n Z 258
p-valueb
Age, n(%) 0.80
40e49 7(4.0) 11(4.3)
50e59 48(27.4) 54(20.9)
60e69 94(53.7) 130(50.4)
>69 26(14.9) 63(24.4)
Smoking habits, n(%) 0.41
ex 94(53.7) 149(57.8)
current 81(46.3) 109(42.2)
GOLD stage, n(%) 0.04
II 91(52.0) 113(43.8)
III 72(41.1) 108(41.9)
IV 12(6.9) 37(14.3)
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Bivariate associations were tested with chi-square tests for
categorical variables and independent-sample t-test or
non-parametric Mann Whitney test for continuous vari-
ables, depending on distribution. Odds ratios (OR) with 95%
confidence Intervals (CI) for having a GFR < 60 were esti-
mated using logistic regression analysis. Examined explan-
atory factors were sex, age, smoking habits, GOLD stage,
Charlson score, estimated from Charlson’s comorbidity
index,21,22 exacerbation history, hypoxemia, cachexia, use
of inhaled steroids, use of angiotensin converting enzyme-
inhibitors (ACE inhibitors) or angiotensin II receptors
blockers (ARBs), and the inflammatory plasma markers CRP,
sTNF-R1 and NGAL. P-values < 0.05 were considered
statistically significant. All statistical analyses were carried
out using Stata version 11.Hypoxemia
(Pa02 < 8.0 kPa), n(%)
0.25
No 128(84.8) 214(88.8)
Yes 23(15.2) 27(11.2)
Exacerbations the last year 0.08
<2 138(78.9) 220(85.3)
2 or more 37(21.1) 38 (14.7)
Cachexia 0.64
No 120(69.4) 183(71.5)
Yes 53(30.6) 73(28.5)
Daily use of inhaled
steroids, n(%)
0.04
No 45(27.7) 90(34.9)
Yes 130(74.3) 168(65.1)
Charlson comorbidity
index, n(%)
0.01
1 113(64.6) 137(53.5)
2 42(24.0) 60(23.4)
3 or more 20(11.4) 59(23.0)
Used ACE inhibitors and/or
ARBs, n(%)
0.07
No 140(80.0) 187(72.5)
Yes 35(20.0) 71(27.5)
a Plasma creatinine measured on 422 of the patients.
b Chi-square test.Results
The baseline characteristics of the COPD patients are
shown in Table 1. The men had more severe COPD judged
by GOLD stage, but were less likely to use inhaled steroids
daily, compared with women. Male patients were more
likely to have a larger burden of comorbidities (Charlson
score) and were less likely than female patients to be daily
smokers (Table 1).
The baseline characteristics of the 233 subjects without
COPD have been previously published.12 Among the 231
subjects without COPD for which we had valid plasma creat-
inine measurements, only 2 subjects had undiagnosed renal
failure (definedashavingaGFR<60), aprevalenceof0.8%. In
contrast, the prevalence of undiagnosed renal failure in the
COPD patients was 6.9%, significantly higher than among the
subjects without COPD (p < 0.001, Fishers exact test).
Stratified by sex, the prevalence of undiagnosed renal
failure was 9.6% in female COPD patients and 5.1% in male
COPD patients (Table 2). Undiagnosed renal failure was not
present in COPD patients under 55 years of age, but
reached a prevalence of 12.7% in COPD patients over 65
years of age. Although there was a trend that undiagnosed
renal failure was more common in COPD patients in GOLD
stage IV, among those who had frequent exacerbations, and
in COPD patients with more comorbidities, none of these
trends were statistically significant. However, in COPD
patients with cachexia, the prevalence of undiagnosed
renal failure was 16.3% compared to 3.0% in COPD patients
without cachexia (p < 0.01, Table 2).
The plasma levels of the three inflammatory markers
CRP, sTNF-R1, and NGAL, in COPD patients with and without
undiagnosed renal failure are shown in Table 3. Both sTNF-
R1 and NGAL was significantly elevated in patients with
undiagnosed renal failure, whereas CRP was not.
The multivariable logistic regression analysis is shown in
Table 4. Generally, the multivariable analysis confirmed the
results from the bivariate analyses. Female sex, higher age,
and cachexia were strong clinical predictors of having
undiagnosed renal failure. A higher GOLD stage and having
frequent exacerbations trended toward higher risk for
undiagnosed renal failure, but failed to reach statistical
significance. Plasma levels of CRP were insignificant, butfor both sTNF-R1 and NGAL did higher systemic levels
predict higher risk for undiagnosed renal failure, also after
adjustment (Table 4).
Discussion
Among COPD patients, female sex, higher age, and cachexia
were strong predictors of risk for undiagnosed renal failure.
In contrast, important COPD disease characteristics like
GOLD stage, exacerbation frequency, hypoxemia, and use of
inhaled steroids failed to show a significant relationship with
risk for renal failure in our COPD patients. Systemic inflam-
mationmeasured by CRP did not predict risk for undiagnosed
renal failure in this population, but the more specific
inflammatory markers sTNF-R1 and NGAL did.
There are some methodological issues to discuss. Firstly,
the study sample was not randomly selected, and the
Table 2 The prevalence (%) of renal failure according to
disease characteristics in a cohort of 422 COPD patients.
n GFR < 60 pa
Overall 422 6.9%
Sex 0.08
Women 167 9.6%
Men 255 5.1%
Age <0.001
40e49 18 0.0%
50e59 99 1.0%
60e69 220 5.9%
>69 85 17.7%
Smoking habits 0.62
ex 237 6.3%
current 185 7.6%
GOLD stage 0.49
II 197 5.6%
III 176 7.4%
IV 49 10.2%
Hypoxemia (PaO2<8.0 kPa) 0.93
No 333 6.6%
Yes 48 6.3%
Exacerbations the last year 0.29
<2 350 6.3%
2 or more 72 9.7%
Cachexia <0.001
No 299 3.0%
Yes 123 16.3%
Daily use of inhaled steroids 0.66
No 130 7.7%
Yes 292 6.5%
Charlson Comorbidity Index 0.17
1 243 5.4%
2 101 6.9%
3 or more 78 11.5%
Used ACE inhibitors and/or ARBs 0.22
No 366 6.3%
Yes 56 10.7%
a Chi-square test.
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were recruited. The subjects without COPD were recruited
from a previous randomly sampled general population
survey. However, for the present study, which was theTable 3 The levels of three inflammatory markers in
COPD patients with and without renal failure.
GFR < 60 GFR > 60 pa
CRP, ug/mL 0.43
median (IQR) 3.19
(1.23e9.01)
4.24
(1.94e10.44)
sTNF-R1, ng/mL <0.01
median (IQR) 7.88
(6.90e12.80)
6.85
(5.69e8.24)
NGAL, pg/mL <0.001
median (IQR) 103.6
(72.3e129.2)
66.0
(50.7e92.7)
a Kruskal Wallis test.baseline phase of a three-year cohort study, subjects were
voluntarily included and did therefore not represent
a random population sample. It is likely that our control
population sample may be a little healthier than the source
population, and that our prevalence of undiagnosed renal
failure is lower than that seen in the general population
aged 40e76 years. This is supported by findings from a large
general population survey from Nord-Trondelag County (the
HUNT survey) in Norway.23 In that sample of over 60 000
subjects, GFR was estimated based on sampled serum
creatinine and the MDRD formula. In the HUNT survey, the
prevalence of renal failure was found to be 2.0% in subjects
50e59 years old, 6.5% in subjects 60e69 years old, and
13.7% in subjects 70e79 years old.23 Importantly however,
whether the subjects in the HUNT survey knew they had
renal failure or not was unknown. Our study only assessed
undiagnosed renal failure, and subjects with known renal
failure were prevented from inclusion.
The COPD patients were recruited from several sources
including a previous COPD study from the Hordaland County
in Western Norway conducted at the Haukeland University
Hospital (‘GenKOLS’, n Z 270),24 the outpatient clinic at
Haukeland University Hospital (nZ 107), outpatient clinics
from other hospitals in Western Norway (nZ 22), and from
the clinics of private lung specialists practicing in Horda-
land County (n Z 34). The Department of Thoracic Medi-
cine, Haukeland University Hospital, has both a local
function and serves as the referral center for pulmonary
disorders in Western Norway. Thus, the range of patients
seen at the outpatient clinic is quite large. However,
selection of patients from the outpatient clinic of a hospital
usually means selecting the most severe cases among
patients, with more polypharmacy, and more comorbid-
ities. Thus, if our patients differ from the COPD patient
population as a whole, including patients seen only by
general practitioners, it is likely that our study population
include patients with more severe disease. Regardless, we
did not establish a relationship between disease severity
and undiagnosed renal failure except for cachexia, and
believe it unlikely that the COPD population as a whole
would have a higher prevalence of undiagnosed renal
failure than the one measured in this study.
Secondly, for Charlson score the ORs from the adjusted
multivariable analysis were opposite what was found in the
bivariate analyses. This was due to the adjustment for the
inflammatory markers. In a model not including the three
markers, Charlson score had ORs (95% CI) of 1.2 (0.4e3.8)
for a score of two, and 2.1 (0.7e6.8) for a score of three or
more. There was no significant interaction between any of
the markers and Charlons score (p > 0.05 for all three, data
not shown). Although the ORs for Charlson score in the
model not including the three inflammatory markers were
not statistically significant, the trend was that more
comorbidities implied higher risk for undiagnosed renal
failure.
Thirdly, we have previously shown that plasma levels of
CRP, sTNF-R1, and NGAL was higher in COPD patients than
in subjects without COPD.12,25 The current study shows that
undiagnosed renal failure in patients with COPD may be
associated with systemic inflammation. NGAL is an antimi-
crobial peptide actively secreted from neutrophils,
epithelial cells, endothelial cells and tubuli cells in the
Table 4 The associations between COPD disease charac-
teristics and undiagnosed renal failure.
n OR (95% CI) p
Sex 0.02
Women 140 1
Men 228 0.25 (0.08e0.77)
Age <0.01
per 10 years increase 368 6.25 (1.83e21.32)
Smoking habits 0.35
ex 205 1
current 163 1.77 (0.53e5.92)
GOLD stage 0.58
II 177 1
III 151 1.38 (0.42e4.55)
IV 40 2.92 (0.41e6.24)
Hypoxemia
(PaO2 < 8.0 kPa)
0.69
No 322 1
Yes 46 0.42 (0.08e2.27)
Exacerbations the
last year
0.69
<2 313 1
2 or more 55 1.36 (0.30e6.24)
Cachexia 0.03
No 262 1
Yes 106 4.03 (1.15e14.07)
Daily use of inhaled
steroids
0.75
No 114 1
Yes 254 0.83 (0.26e2.67)
Charlson Comorbidity
Index
0.74
1 219 1
2 87 0.67 (0.17e2.68)
3 or more 62 0.55 (0.10e2.90)
Used ACE inhibitors
and/or ARBs
0.32
No 327 1
Yes 41 2.28 (0.45e11.51)
CRP
per 1 ug/mL increase 368 0.95 (0.88e1.03) 0.19
sTNF-R1
per 100 ng/mL increase 368 1.26 (1.00e1.58) <0.01
NGAL
per 10 ng/mL increase 368 1.32 (1.10e1.58) 0.048
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and NGAL are a cause or effect of undiagnosed renal failure
cannot be inferred from this cross-sectional study.
Finally, we chose the Cockcroft Gault formula for
defining renal failure. This formula takes into account sex,
age, creatinine, and the weight of the subject. Creatinine
varies with muscle mass and thus weight, and formulas not
taking weight into account tend to underestimate GFR in
subjects with large muscle mass, and overestimate GFR in
subjects with smaller muscle mass.27 The Cockcroft Gault
formula does not take race into account. In our study
sample, the study subjects had Caucasian background save
one subject, who was of South American origin. Thus, webelieve lack of adjustment for race was unimportant,
whereas adjustment for weight was important for our
cohort of COPD patients.
Comparedwith the Italian study of 356 COPD patients, we
found amuch lower prevalence of undiagnosed renal failure,
6.9%e21%. There are several possible explanations for this.
Firstly, the Italian study subjects were older, all participants
more than 65 years. Age was found in both studies to be an
independent risk factor for undiagnosed renal failure. In our
study sample the prevalence of undiagnosed renal failure in
subjects above 65 years of age was 12.7%. Secondly, the
Italian study used the Modification of Diet in Renal Disease
(MDRD) formula, which does not take weight into account.
The mean body mass index (BMI) in the patients with undi-
agnosed renal failure in the Italian study was 29.2 kg/m2,
which is rather high. Thus, it is possible that their use of the
MDRD formula led to an overestimation of renal failure.
Thirdly, their patients were recruited from outpatient clinics
in several hospitals in Italy, and the difference in prevalence
could be explained by differences in study populations.
Finally, the difference might reflect that the prevalence of
undiagnosed renal failure actually is higher in Italian COPD
patients than in Norwegian COPD patients.
This study underscores the importance of being vigilant
about comorbidities in COPD patients. Undiagnosed renal
failure is arguably a poorly recognized comorbidity in
COPD, however it is not trivial, and COPD patients often use
several medications that are metabolized through the
kidneys. We urge physicians to be vigilant for this potential
comorbidity.
The finding that COPD patients with cachexia were at
increased risk for undiagnosed renal failure is a novel
finding. It is well known that advanced renal failure leads to
cachexia,28 however that does not apply to the patients in
this study. On the contrary, this finding could imply that
COPD patients who are in a catabolic state may be at
increased risk for developing renal failure. However, this
theory would also need to be confirmed in longitudinal
studies.
In conclusion, in this study the prevalence of undiag-
nosed renal failure was found to be about 7% among
patients with COPD. Female sex, higher age, cachexia, and
the systemic inflammatory markers sTNF-R1 and NGAL
predicted a higher risk for having undiagnosed renal failure
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